Skip to main content

Illumina (US), Thermo Fisher (US), and QIAGEN (Netherlands)—Major Players in the Global Epigenetics Market

The global epigenetics market is projected to reach USD 1,605.7 Million by 2022 from USD 854.0 Million in 2017, at a CAGR of 13.5% from 2017 to 2022. Favorable government funding initiatives for epigenetics research, increasing research activities, decreasing sequencing costs & time, and rising prevalence of cancer are the key factors driving market growth

Key players in the global epigenetics market, such as Illumina, Thermo Fisher, Diagenode, Merck Millipore, Abcam, Active Motif, New England Biolabs, Agilent, Zymo Research, and PerkinElmer, are focusing on increasing their presence in the high-growth markets through organic as well as inorganic strategies such as product launches, partnerships, agreements, collaborations, expansions, and acquisitions.

http://www.marketsandmarkets.com/ResearchInsight/epigenetics-technologies-market.asp

Illumina dominated the global epigenetics market in 2016. The company provides sequencing and array-based solutions for genetic analysis. It develops, manufactures, and markets integrated systems and life science tools for the analysis of genetic variation and biological function. Illumina operates through 26 subsidiaries located in the US, the UK, and other countries in Europe and the Asia Pacific regions. In order to achieve high growth and increase its customer base, the company focuses on organic and inorganic strategies such as product launches, collaborations, and agreements. For instance, in January 2017, Illumina launched a NovaSeq instruments series. During the same period, the company entered into a collaboration agreement with Philips (Netherlands) to integrate its sequencing systems with Philips’ IntelliSpace Genomics clinical informatics platform for oncology.

Thermo Fisher is another prominent player in the epigenetics market. The company develops and manufactures high-end analytical instruments, laboratory equipment, software, consumables, reagents, and services for scientific research, analysis, discovery, and diagnostics. It operates in more than 180 countries across North America, Europe, Asia, Middle East, Africa, and Latin America. To strengthen its position in the epigenetics market, the company pursues organic as well as inorganic growth strategies. For instance, in June 2017, the company expanded its mass spectrometers portfolio with the launch of the Q Exactive HF-X Hybrid Quadrupole Orbitrap. Similarly, in September 2016, the company opened its new global headquarters at 168 Third Avenue in Waltham, Massachusetts (US).

Related Reports:
Epigenetics Market by Product (Kit, Enzymes, Reagent, NGS, Mass Spectrometer, PCR, Bioinformatics), Application (Oncology, Cardiology, Immunology), Technology (DNA Methylation, Histone Modification), End User (Academic, CRO) – Global Forecast to 2022

Contact:
Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
Labels:

Comments

  1. Jhon mac8 July 2019 at 07:51

    Thanks for your great and helpful presentation I like your good service.I always appreciate your post. Excellent information on your blog, thank you for taking the time to share with us.
    Genomind

    ReplyDelete

Post a Comment

Popular posts from this blog

NGS-Based RNA-Sequencing Industry is Growing at a CAGR of 20%

NGS-based RNA-sequencing Market growth is driven mainly by the advantages of RNA-seq over conventional technologies; an increasing number of RNA-seq grants; rising number of research activities involving RNA-seq; and rapid growth in precision medicine market. NGS-based RNA-sequencing Market: Impact Analysis 1. NGS-Based RNA-Sequencing: Market Overview 2. Geographical Snapshot of the NGS-Based RNA-Sequencing Market 3. Rapid Growth in Precision Medicine 4. Growing Number of Research Activities Involving RNA-Seq 5. Increasing Applications of RNA-Seq in Research ( Cancer and Agricultural) The NGS-based RNA-sequencing market size is estimated to grow from USD 1.7 billion in 2019 to USD 4.2 billion by 2024, at a CAGR of 20.0%. Key Questions Addressed in The Report: 1. Who are the top 10 players operating in the global NGS-based RNA-sequencing market? 2. What are the drivers, restraints, opportunities, and challenges in the NGS-based RNA-sequencing Industry? 3. What are th...
Post a Comment
Read more

Digital Diabetes Management Market to Reach $19.98 billion by 2024 | Market and Regional Growth Analysis

  Digital diabetes management solutions are smartphone-connected diabetes management devices and software platforms used by patients suffering from Type 1, Type 2, and gestational diabetes. Medical professionals also use these solutions to manage diabetes. Various digital diabetes management devices such as smart glucose meters, continuous glucose monitoring systems, smart insulin pens, and smart insulin pumps/closed-loop systems and smart insulin patches are used for glucose monitoring and insulin delivery. Diabetes management applications, data management software & platforms, and services are used by patients and healthcare providers for remote monitoring, data analysis, and disease management. The Digital Diabetes Management Market is experiencing significant growth due to rising prevalence of diabetes has increased the focus on the development and adoption of better solutions for diabetes care. Also, advancements in technologies have ensured the introduction of highly...
Post a Comment
Read more

Epigenetics Market | Major Market Dynamics Impacting The Global Industry

Epigenetics refers to the covalent modification of DNA, RNA, or protein that results in changes to the function and/or regulation of these molecules, without altering their primary sequences. These modifications can occur naturally, or can be influenced, by several factors including age, environment, disease state, and changes in lifestyle. Expanding application areas of epigenetics in non-oncology diseases, personalized medicine, and target therapy are expected to provide growth opportunities for players operating in the epigenetics market in the coming years. The growth in this market is primarily attributed to decreasing sequencing costs, increasing research activity, funding for epigenetics research, rising prevalence of cancer and growing applications of epigenetics in non-oncology diseases. Epigenetic changes such as dysregulation of DNA methylation are associated with cancer development and progression. Epigenetics provides new opportunities for deriving therapeutic strateg...
Post a Comment
Read more